Use: Labeled indications
- LEVOPHED is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE LEVOPHED is indicated to raise blood pressure in adult patients with severe, acute hypotension. LEVOPHED is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. (1)
Contraindications
4 CONTRAINDICATIONS None. None. (4)
US FDA labelDosing: Adult
- • Initial dose of 0.25 mL to 0.375 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low to normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation of vital organs. (2.2)
- • The average maintenance dose ranges from 0.0625 mL to 0.125 mL per minute (from 2 mcg to 4 mcg of base). (2.2)
2.1 Important Dosage and Administration Instructions Correct Hypovolemia
2.1 Important Dosage and Administration Instructions Correct Hypovolemia Address hypovolemia before initiation of LEVOPHED therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions (5.1)]. Administration Dilute LEVOPHED prior to use [see Dosage and Administration (2.3)].
Infuse LEVOPHED into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see Warnings and Precautions (5.1)]. Avoid using a catheter-tie-in technique. Discontinuation When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal.
2.2 Dosage
2.2 Dosage After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion.
Typical maintenance intravenous dosage is 2 to 4 mcg per minute.
2.3 Preparation of Diluted Solution
2.3 Preparation of Diluted Solution Visually inspect LEVOPHED for particulate matter and discoloration prior to administration (the solution is colorless). Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate. Add the content of one LEVOPHED vial (4 mg in 4 mL) to 1,000 mL of 5% Dextrose Injection, USP or Sodium Chloride Injection solutions that contain 5% dextrose to produce a 4 mcg per mL dilution.
Dextrose reduces loss of potency due to oxidation. Administration in saline solution alone is not recommended. Use higher concentration solutions in patients requiring fluid restriction. Prior to use, store the diluted LEVOPHED solution for up to 24 hours at room temperature [20°C to 25°C (68°F to 77°F)] and protect from light.
2.4 Drug Incompatibilities
2.4 Drug Incompatibilities Avoid contact with iron salts, alkalis, or oxidizing agents. Whole blood or plasma, if indicated to increase blood volume, should be administered separately.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of LEVOPHED did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Avoid administration of LEVOPHED into the veins in the leg in elderly patients [see Warnings and Precautions (5.1)].
Administration
2.1 Important Dosage and Administration Instructions Correct Hypovolemia Address hypovolemia before initiation of LEVOPHED therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions (5.1) ] . Administration Dilute LEVOPHED prior to use [see Dosage and Administration (2.3) ] . Infuse LEVOPHED into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see Warnings and Precautions (5.1) ]. Avoid using a catheter-tie-in technique . Discontinuation When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal.
2.2 Dosage After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion. Typical maintenance intravenous dosage is 2 to 4 mcg per minute.
2.3 Preparation of Diluted Solution Visually inspect LEVOPHED for particulate matter and discoloration prior to administration (the solution is colorless) . Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate. Add the content of one LEVOPHED vial (4 mg in 4 mL) to 1,000 mL of 5% Dextrose Injection, USP or Sodium Chloride Injection solutions that contain 5% dextrose to produce a 4 mcg per mL dilution. Dextrose reduces loss of potency due to oxidation. Administration in saline solution alone is not recommended. Use higher concentration solutions in patients requiring fluid restriction. Prior to use, store the diluted LEVOPHED solution for up to 24 hours at room temperature [20°C to 25°C (68°F to 77°F)] and protect from light.
2.4 Drug Incompatibilities Avoid contact with iron salts, alkalis, or oxidizing agents. Whole blood or plasma, if indicated to increase blood volume, should be administered separately.
US FDA labelDosage forms
Philippines
- ) solution for injection: 1 mg/1 mL (4 mg/4 mL, 1 mg/mL ( 2 mg/2 mL, 1 mg/mL (2 mg/2 mL) and (4 mg/4 mL, 1 mg/mL (2 mg/2 mL, 4 mg/4 mL and 10 mg/10 mL, 1 mg/mL (20 mg/20 mL, 1 mg/mL (4 mg/4 mL, 1 mg/mL (4 mg/4 mL and 10 mg/10 mL, 2 mg/mL (8 mg/4 mL
- Concentrated solution for i.v. injection: 1 mg/mL
- Solution for injection: 1 mg/mL, 2 mg/2 mL, 2 mg/mL
- Concentrate solution for iv infusion: 1 mg/mL
- Concentrate solution for i.v. infusion: 1 mg/mL
- ) concentrated solution for iv infusion: 2 mg/mL (8 mg/4 mL
- ) concentrate solution for injection for i.v. infusion: 1 mg/mL (4 mg/4 mL
- ) solution for iv infusion: 1 mg/mL (4 mg/4 mL, 2 mg/mL (8 mg/4 mL
- ) solution for iv injection: 1 mg/mL (4 mg/4 mL
- ) concentrate for solution for i.v. infusion: 1 mg/mL (4 mg/4 mL
and 11 more forms; see the products table.
Registered products in the Philippines
128 products registered with the Food and Drug Administration (FDA) Philippines list Norepinephrine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products128
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AdrenorphrineNorepinephrine (as bitartrate) | 1 mg/mL Solution For Injection (I.V.)USP Type I amber colored glass ampoule x 2 mL, 4 mL, 8 mL & 10 mL in a PVC plastic tray (Box of 1’s, 5's & 10’s) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel Abbas Pharmaceuticals & General Merchandise | DRP-18814 | Sep 16, 2031 | |
AenopNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 4 mL, 8 mL, 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Pors Pharma Trading | DRP-16027-05 | Apr 29, 2029 | |
AenorNorepinephrine (as bitartrate) | 1 mg / ml (4 mg / 4 ml) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL -capacity Type I amber glass ampoule (5 ampoules in clear PVC blister tray per box) (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Dynasty PharmaceuticalsImporter: Despina Pharma, Inc. | DRP-14777-02 | Jan 3, 2029 | |
AenorNorepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Dynasty PharmaceuticalsImporter: Despina Pharma Inc. | DRP-14776-02 | Jan 3, 2029 | |
BlinephNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929 | Jan 31, 2027 | |
BlinorNorepinephrine (as bitartrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Corbridge Group Phils., Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-06 | Jan 31, 2027 | |
Blu-PhinorNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for I.V. InfusionUSP Type I Amber glass ampoule x 4 mL (Box of 10's) | Rx | Kilitch Drugs (India) Ltd.India | Blu EnterprisesImporter: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11623-03 | May 9, 2028 | |
BP-UPNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | UNILAB, INC.Importer: JLT Pharma Inc. | DRP-8929-16 | Jun 17, 2031 | |
BrixephrineNorepinephrine | 1mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Brixmed Pharma Care, Inc.Importer: Pors Pharma Trading | DRP-16027-02 | Apr 29, 2029 | |
CentranorNorepinephrine (as bitartrate monohydrate) | 1 mg/mL (4 mg/4 mL) Concentrate for Solution for I.V. Infusion4 mL-net content Type I amber glass ampoule (Box of 10's) | Rx | Mefar İlaç San. A.Ş.Turkey | Grovic Pharma, Inc.Trader: Pharmada İlaç San. Ve Tic A.Ş. | DRP-14873 | Jan 26, 2029 | |
Desphrine 1Norepinephrine (As Bitartrate) | 1 mg/mL Solution For Injection (IV)Type I Amber Glass Ampoule x 2 mL, 4 mL, 8 mL, and 10 mL (Box of 1's, 5's and 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Despina Pharma Inc. | DRP-18822 | Sep 14, 2031 | |
Desphrine 2Norepinephrine (as bitartrate) | 2 mg/mL Solution For Injection (IV)Type I Amber Glass Ampoule 2 mL, 4 mL, 8 mL and 10 mL (Box of 1's, 5's and 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Despina Pharma Inc. | DRP-18823 | Sep 14, 2031 | |
Despinor 1Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14777-06 | Jan 3, 2029 | |
Despinor 2Norepinephrine (as bitartrate) | 2 mg / mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14776-09 | Jan 3, 2029 | |
DopaqureNorepinephrine (as bitartrate) | 1 mg/mL (2 mg/2 mL, 4 mg/4 mL and 10 mg/10 mL) Solution for Injection (1.V.)USP Type I Amber Glass Ampoule x 2 mL x 4 mL x 10 mL (Box of 10's and 5's) | Rx | Celon Laboratories Private LimitedIndia | Tamiga Pharmaceuticals SupplyImporter: I.E. Medica, Inc. | DRP-5072-03 | Apr 4, 2031 | |
EliphineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution For Injection IV InfusionAmber glass ampoule x 4 mL in 5 mL (Box of 5's in clear PVC blister tray) | Rx | Kwality Pharmaceutical Ltd.India | Elixir Pharma Inc. | DRP-18711 | Aug 26, 2031 | |
EliphineNorepinephrine (as bitartrate) | 2 mg / mL (8 mg / 4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL- capacity Type I amber glass ampoule (5 ampoule in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Elixir Pharma Inc.Importer: Despina Pharma, Inc. | DRP-14776-07 | Jan 3, 2029 | |
EliphineNorepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution For IV InfusionAmber glass Ampoule x 4 mL in 5 mL (Box of 5's in Clear PVC Blister Tray) | Rx | Kwality Pharmaceutical Ltd.India | Elixir Pharma Inc. | DRP-18712 | Sep 8, 2031 | |
ElsonNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V.)4 mL Amber Glass Ampoule with PVC/PVDC Tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc. | DRP-8929-06 | Jun 13, 2031 | |
EphreeNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL ( Box of 5's ) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-10 | Jan 31, 2027 | |
EpibestNorepinephrine | 1 mg / mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 8 mL (Box of 5's) | Rx | Med Biopharma Pvt. Ltd.India | Best ClearImporter: Pors Pharma Trading | DRP-16027-09 | Apr 29, 2029 | |
EPINORNOREPINEPHRINE (as bitartrate) | 1mg/mL (10mg/10mL)Solution for Injection (I.V)USP Type I amber glass Ampoule x 2mL Box of 10's; USP Type I amber glass Ampoule x 4mL Box of 5's; USP Type I amber glass Ampoule x 10mL Box of 5's; USP Type I amber glass Ampoule x 10mL Box of 10's | Rx | CELON LABORATORIES PRIVATE LIMITEDIndia | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-5072-02 | Oct 26, 2031 | |
Epinorine 1Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14777-01 | Jan 3, 2029 | |
Epinorine 2Norepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14776-01 | Jan 3, 2029 | |
EpinylNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4mL) Solution for Injection (IV/IV Infusion)4 mL and 10 mL (Net Content) Type I Amber Glass Ampoule (Box of 5's and 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-14742-02 | Nov 19, 2029 | |
ExeprinNorepinephrine (as bitartrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | HLM Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-12 | Jan 31, 2027 | |
FreeronNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-08 | Jan 31, 2027 | |
HypoactNorepinephrine (as bitartrate) | 1 mg/ mL Concentrate Solution for IV Infusion4 mL in 5 mL-capacity Type I clear glass ampoule (Box of 10's) | Rx | Laboratoire AguettantFrance | The Cathay Drug Co., Inc. | DR-XY46883 | May 15, 2030 | |
HypomedNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Ambles Glass Ampoule x 5mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | AJ Research & Pharma Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-05 | Jan 31, 2027 | |
JaznorNorepinephrine (as bitartrate) | 1 mg/1 mL (4 mg/4 mL) Solution for Injection (IV/IV Infusion)4 mL and 10 mL (Net Content) Type I Amber Glass Ampoule (Box of 5's and 10’s) | Rx | Kwality Pharmaceuticals Ltd.India | JazMark PharmaceuticalImporter: Pharma-Surrey International, Inc. | DRP-14742-01 | Nov 19, 2029 | |
LevofinNorepinephrine (as Bitartrate) | 1 mg/mL Solution for Injection (IV)Type I Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Huons Co., LtdKorea | INTERNATIONAL APEX PHARMACEUTICAL, INC.Importer: Endure Medical, Inc. | DRP-3695-01 | Jun 14, 2028 | |
LevomefNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Josmef EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-17 | Jan 31, 2027 | |
LevophaNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4mL and 10mg/10mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC tray x 4mL and 10mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | AGCC MarketingImporter: JLT Pharma Inc. | DRP-8929-11 | Jul 31, 2031 | |
Levophed SF (Sulfite-Free)Norepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for IV InfusionType I Colourless Glass Ampoule in Box of 1 Blister Tray x 5's [2mL ampoule (w/ 2mL filled volume); Type I Colourless Glass ampoule in Box of 1 Blister Tray x 5's [5mL ampoule (w/ 4mL filled volume)] | Rx | Avara Liscate Pharmaceutical Services S.p.AItaly | Pfizer, Inc | DR-XY38195 | Jul 7, 2037 | |
MephrinNorepinephrine (as Bitartrate) | 2 mg/mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 4 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Marcburg Philippines Inc. | DR-XY44919 | Nov 25, 2028 | |
MyophrineNorepinephrine | 2 mg/mL Concentrate Solution for I. V. Infusion4 mL USP Type I amber glass ampoule in PVC tray x 10's (Box of 10's) | Rx | Friends Pharma (Pvt). Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-16997 | Sep 5, 2031 | |
NefrinorNorepinephrine (as bitartrate monohydrate) | 1 mg/mL (4 mg/4 mL) Solution for Infusion (I.V.)4 mL-net content Type I amber glass ampoule (Box of 10's) | Rx | Mefar İlaç Sanayii A.Ş.Turkey | Endure Medical, Inc.Trader: Incpharma İlaç San. ve Tic. Ltd. Şti. | DR-XY49030 | Mar 27, 2029 | |
NepinNorepinephrine (as bitartrate) | 1 mg/mL Solution for Injection (IV)USP Type I amber glass ampoule x 4 mL (Box of 5's) | Rx | PT. Pratapa NirmalaIndonesia | PharmAsia-Cuvest, Incorporated | DRP-7961 | Jul 18, 2030 | |
Nepriqo 4Norepinephrine (as bitartrate) | 1 mg / ml (4 mg/4 ml) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Amediqo Phils., Inc.Importer: Despina Pharma Inc. | DRP-14777-04 | Jan 3, 2029 | |
Nepriqo 8Norepinephrine (as bitartrate) | 2 mg / ml (8 mg /4 ml) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Amediqo Phils., Inc.Importer: Despina Pharma, Inc. | DRP-14776-04 | Jan 3, 2029 | |
NeurophrineNorepinephrine (as bitartrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-04 | Jan 31, 2027 | |
NeurosenzNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/ 4 mL) Solution for IV InjectionUSP Type I Glass Ampoule x 4 mL (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Korea | H & B Pharma International Inc..Trader: Dalim Biotech Co., Ltd. | DRP-15794 | Sep 18, 2029 | |
NoneNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 8 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Tamiga Pharmaceuticals SupplyImporter: Pors Pharma Trading | DRP-16027-06 | Apr 29, 2029 | |
NoneNorepinephrine (as bitartrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I amber glass ampoule x 5mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Redjensons Medical CorporationImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-16 | Jan 31, 2027 | |
NoneNorepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Pharma King DistributorImporter: Despina Pharma Inc. | DRP-14776-10 | Jan 3, 2029 | |
Nor-EpNorepinephrine (as bitartrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Sonchel Pharma DistributorsImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-02 | Jan 31, 2027 | |
Nor-EpixNorepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Concentrated Solution for IV Infusion4 mL USP Type I glass ampoule in a plastic tray x 10's (Box of 10's) | Rx | Grand Pharmaceutical (China) Co., Ltd.China | AGlobal Care Inc. | DRP-16865 | Aug 1, 2030 | |
NorbipineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for IV Infusion5 mL capacity Type 1 Clear Glass Ampoule x 4 mL (Box of 10's) | Rx | UBI Pharma Inc.(Hsinchu Plant)Taiwan | Neo Care Philippines,Inc.Trader: Peili Pharmaceutical Ind .Co.Ltd. | DRP-12718 | Sep 28, 2030 | |
NorbitNorepinephrine (as Bitartrate) | 1 mg/mL ( 2 mg/2 mL) Solution for Injection ( I.V)USP Type I Amber Glass Ampoule x 2 mL (Box of 2's and 10's); USP Type I Amber Glass Ampoule x 4 mL (Box of 2's and 5's); USP Type I Amber Glass Ampoule x 10 mL (Box of 10's and 5's) | Rx | Celon Laboratories Private LimitedIndia | I.E Medica, Inc. | DRP-5072 | Apr 4, 2031 | |
NordixNorepinephrine (As Bitartrate) | 1 mg/mL Concentrate Solution For Iv InfusionUSP Type I amber glass ampoule in clear plastic tray x 4 mL (Box of 10's) and 10 mL (Box of 5's) | Rx | Permit Guizhou Tiandi Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc. | DRP-18747 | Sep 3, 2031 | |
NorecentNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule x 4 mL and 10 mL with PVC/PVDC Tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-8929-09 | Jul 6, 2031 | |
Norecent-20Norepinephrine (as bitartrate) | 1 mg/mL (20mg/20mL) Solution for Injection (IV)USP Type I Amber glass ampoule in PVC/PVDC Tray x 5’s (Box of 10’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-17214-01 | Oct 20, 2030 | |
NorecorNorepinephrine | 2 mg/mL (8 mg/4 mL) Concentrated Solution for IV InfusionAmber Glass Ampoule in Blister Pack x 5mL (Box of 5's) | Rx | Nichepharm Lifesciences Pvt. Ltd.India | Cor Magna Pharmaceuticals Holding Inc.Importer: Seapharma International, Inc. | DRP-16732-01 | Jul 1, 2030 | |
NoredecNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 4mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Deca Med Pharmaceutical Trading Inc.Importer: Pors Pharma Trading | DRP-16027-03 | Apr 29, 2029 | |
NorediNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for IV InfusionAmber glass ampoule x 4 mL and 10 mL with white snap off ring (Box of 5's in a plastic tray) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17202 | Oct 20, 2030 | |
NorefierNorepinephrine | 1 mg / mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Fier Pharma Trading Inc.Importer: Pors Pharma Trading | DRP-16027-01 | Apr 29, 2029 | |
Noremarc 8Norepinephrine | 1mg/mL (8mg/8mL) Concentrate Solution For Infusion (I.V.)Clear glass ampoule in plastic tray x 5's (Box of 10's) | Rx | HBM Pharma S.R.OSlovak Republic | Marcburg Philippines Inc.Trader: Akciju sabiedriba "Kalceks" | DRP-14056 | Jun 9, 2028 | |
NoremedNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 4 mL, 6ml, 8 mL, 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Blue Medceuticals Marketing Corp.Importer: Pors Pharma Trading | DRP-16027-07 | Apr 29, 2029 | |
NoreminNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg / 10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | IMJ Medica Inc.Importer: JLT Pharma Inc. | DRP-8929-15 | Jul 14, 2031 | |
NorenNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | JustRight Healthcare Inc.Importer: JLT Pharma Inc. | DRP-8929-17 | Jul 20, 2031 | |
NorenNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V.)4mL Amber Glass Ampoule with PVC/PVDC Tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | JustRight Healthcare Inc.Importer: JLT Pharma Inc. | DRP-8929-05 | Jul 26, 2031 | |
NorephilzNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule x 4 mL and 10 mL with PVC/PVDC Tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma Inc. | DRP-8929-12 | Jul 6, 2031 | |
NorephilzNorepinephrine (as bitartrate) | 1mg/mL (20mg/20mL) Solution for Injection (IV)USP Type I Amber glass ampoule in PVC/PVDC Tray x 5's (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma Inc. | DRP-17214-04 | Oct 20, 2030 | |
NorephimedNorepinephrine (as Bitartrate) | 1mg/mL (4mg/4mL ) Solution for Injection (IV)Type I Amber Glass Ampoule x 5mL (Box of 5's) | Rx | — | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-01 | Jan 31, 2027 | |
NorephinNorepinephrine (as bitartrate) | 2 mg/ mL (8 mg/ 4mL) Solution for Injection (I.V. Infusion)4 mL -net content in 5 mL -capacity Type I amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Elixir Pharma Inc.Importer: Despina Pharma Inc. | DRP-14776-06 | Jan 3, 2029 | |
NorephstarNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Twostar Pharmaceutical TradingImporter: Pors Pharma Trading | DRP-16027-12 | Apr 29, 2029 | |
NorepidenNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/ 4 mL) Solution for Injection (IV)4 mL Amber Glass Ampoule with White Ring Snap-Off in Plastic Tray x 5's (Box of 5's) | Rx | Farbe Firma Pvt. LtdIndia | Cyden Medicale Trading Inc.Importer: AMB HK Enterprises, Inc. | DRP-13144-02 | Dec 7, 2027 | |
NorepikNorepinephrine (as bitartrate) | 1mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Kurtmed Medical Distribution Inc.Importer: JLT Pharma Inc. | DRP-8929-18 | Jul 14, 2031 | |
NorepillenNorepinephrine (as bitartrate) | 2 mg/mL Solution for Injection (IV)USP Type I amber glass ampoule x 4 mL (net content) in PVC tray x 5's (Box of 5's and 10's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc | DRP-17415 | Dec 12, 2030 | |
NorepiMaxNorepinephrine (as bitartrate monohydrate) | 1mg/mL (4mg/4mL) Concentrate Solution for Injection for I.V. InfusionType I borosilicate clear glass ampoule x 4 mL (Box of 5's) | Rx | PT. BernofarmIndonesia | Dreamax Life Sciences IncorporatedImporter: Dreamax IncorporatedTrader: PT Infion | DRP-13258-01 | Jan 11, 2028 | |
NorepinNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for InfusionUSP Type I Amber Colored Glass Ampoule in 2 mL, 4 mL per Ampoule (Box of 5’s); USP Type I Amber Colored Glass Ampoule in 10 mL per Ampoule (Box of 1’s) | Rx | United Biotech Pvt. LimitedIndia | Delex Pharma International, Inc. | DRP-10472 | Dec 6, 2030 | |
Norepin 16Norepinephrine (as bitartrate) | 1 mg/mL (16 mg/16 mL) Concentrate Solution. for IV Infusion20 mL Amber vial with grey butyl rubber stopper, aluminum seal and green flip-off cap in plastic tray (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | Delex Pharma International, Inc. | DRP-15074 | Apr 12, 2029 | |
Norepinllen-PE2Norepinephrine (as bitartrate) | 2 mg/ml Solution For Injection (I.V. Infusion)4 mL USP Type I amber glass ampoule in PVC tray (Box of 5’s and 10’s) | Rx | Penam Biosciences Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-19014 | Oct 19, 2031 | |
Norepinsaph-1Norepinephrine (As Bitartrate) | 1 mg/mL Concentrate Solution For InjectionUSP Type I Amber glass ampoule x 2 mL (Box of 1's, 5's and 10's), 4 mL (Box of 1's, 5's and 10's), and 10 mL (Net Content: 8 mL) (Box of 1's, 5's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire LifeSciences Pvt. Ltd. | DRP-11623 | Jul 8, 2031 | |
Norepion 1Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14777-05 | Jan 3, 2029 | |
NoreporsNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharma Pvt. Ltd.India | Pors Pharma Trading | DR-XY49061 | Apr 29, 2029 | |
NoreporsNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-16027 | Apr 29, 2029 | |
NorepsinaiNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for I.V. InfusionUSP Type I Amber glass ampoule x 4 mL (Box of 5’s) | Rx | Kilitch Drugs (India) Ltd.India | Oro Sinai Pharma and General Merchandise, Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11623-02 | May 9, 2028 | |
NoreseaNorepinephrine | 2 mg/mL (8 mg/4 mL) Concentrated Solution for IV InfusionAmber Glass Ampoule in Blister Pack x 5 mL (Box of 5's) | Rx | Nichepharm Lifesciences Pvt. LtdIndia | Seapharma International, Inc. | DRP-16732 | Jul 1, 2030 | |
NoretamNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 8 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Tamiga Pharmaceuticals Corp.Importer: Pors Pharma Trading | DRP-16027-08 | Apr 29, 2029 | |
NorfineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV/IV Infusion)4 mL and 10 mL (Net Content) Type I Amber Glass Ampoule (Box of 5's and 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-14742 | Nov 19, 2029 | |
NorfineNorepinephrine (as bitartrate) | 2 mg/2 mL Solution for Injection (I.V.)Type I Amber Glass Ampoule with White Ring on Neck x 2 mL (Box of 10’s) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc | DRP-16390 | Feb 26, 2030 | |
NorfionNorepinephrine (as bitartrate monohydrate) | 1 mg/mL (4 mg/ 4 mL) Concentrate Solution for Injection for I.V. InfusionType I borosilicate clear glass ampoule x 4 mL (Box of 5's) | Rx | PT. BernofarmIndonesia | Dreamax IncorporatedTrader: PT Infion | DRP-13258 | Jan 11, 2028 | |
NorhipineNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for I.V. InfusionUSP Type I Amber glass ampoule x 4 mL (Box of 5's) | Rx | Kilitch Drugs (India) Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11623-04 | May 9, 2028 | |
NoridenNorepinephrine (as Bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | GPC Geo Pharma CorporationImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-11 | Jan 31, 2027 | |
NorifreeNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-09 | Jan 31, 2027 | |
NoriphedNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC tray x 4mL and 10mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Group Inc.Importer: JLT Pharma Inc. | DRP-8929-04 | Jul 20, 2031 | |
NoriphedNorepinephrine (as bitartrate) | 1mg/mL (20mg/20mL) Solution for Injection (IV)USP Type I Amber glass ampoule in PVC/PVDC Tray x 5's (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Group Inc.Importer: JLT Pharma Inc. | DRP-17214-02 | Oct 20, 2030 | |
NoriphenNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Ellebasy Medicale TradingImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-03 | Jan 31, 2027 | |
NorisanNorepinephrine (as bitratrate) | 1mg/mL (4mg/4mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-14 | Jan 31, 2027 | |
NoriterNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)4 mL Amber Glass Ampoule with White Ring Snap-Off in Plastic Tray x 5’s (Box of 5’s) | Rx | Farbe Firma Pvt. Ltd.India | CV Clearvue Pharma, Inc.Importer: AMB HK Enterprises, Inc. | DRP-13144-01 | Dec 7, 2027 | |
NoriterNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for IV InfusionAmber glass ampoule x 4 mL with white snap off ring (Box of 5’s in a plastic tray) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | CV Clearvue Pharma, Inc.Importer: AMB HK Enterprises Inc. | DRP-17202-02 | Oct 20, 2030 | |
NorkenzNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V.)4mL Amber Glass Ampoule with PVC/PVDC Tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-8929-08 | Jul 15, 2031 | |
NormakNorepinephrine (As Bitartrate) | 1 mg/mL Concentrate Solution For IV Infusion5 mL-capacity USP Type I Amber glass ampoule in plastic tray x 4 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Hillcross Prime, Inc. | DRP-11740 | Apr 25, 2027 | |
NormeedNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Meedpharma Medical Supplies & Equipment DistributorImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-15 | Jan 31, 2027 | |
NorphedNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/ 4 mL) Solution for I.V. InjectionUSP Type I Amber coloured glass ampoule with sky blue ring code x 4 mL (Box of 10's) | Rx | Huons Co., Ltd.Korea | Endure Medical, Inc. | DR-XY49183 | Aug 29, 2029 | |
NorphedNorepinephrine (as Bitartrate) | 1 mg/mL Solution for Injection (I.V)Type I amber glass ampoule x 2 mL & 4 mL Box of 10's | Rx | Huons Co., LtdKorea | ENDURE MEDICAL, INC. | DRP-3695 | Jun 14, 2028 | |
NorphoNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | JMN Brothers Pharma Limited Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-07 | Jan 31, 2027 | |
NorphrexNorepinephrine | 2 mg/mL (8 mg/ 4 mL) Solution for Injection (I.V. Infusion)USP Type I amber glass ampoule x 4 mL (Box of 5's) | Rx | Captab Biotec Unit IIIndia | Amediqo Phils., Inc.Importer: Finstad Inc.Trader: Morcel Biotech Pvt. Ltd. | DRP-17306-01 | Nov 14, 2030 | |
Norphrine 1Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type I amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Despina Pharma, Inc. | DRP-14777 | Jan 3, 2029 | |
Norphrine 2Norepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type I amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Despina Pharma, Inc. | DRP-14776 | Jan 3, 2029 | |
NorpressNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Pors Pharma Trading | DRP-16027-11 | Apr 29, 2029 | |
NovaphrineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I amber glass ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Medinova Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-10929-13 | Jan 31, 2027 | |
NupiraNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule x 4 mL and 10 mL with PVC/PVDC tray (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma Inc. | DRP-8929-10 | Jul 6, 2031 | |
NupiraNorepinephrine (as bitartrate) | 1mg/mL (20mg/20mL) Solution for Injection (IV)USP Type I Amber glass ampoule in PVC/PVDC Tray x 5's (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma, Inc. | DRP-17214-03 | Oct 20, 2030 | |
NupiraNorepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Amediqo Phils., Inc.Importer: Despina Pharma Inc. | DRP-14776-05 | Jan 3, 2029 | |
PenorepNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV/IV Infusion)4 mL and 10 mL (Net Content) Type I Amber Glass Ampoule (Box of 5's and 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Planetarium Enterprise, Inc.Importer: Pharma-Surrey International, Inc. | DRP-14742-03 | Nov 19, 2029 | |
PhilnorNorepinephrine(As Bitartrate) | 1 mg/mL (4 mg/4 mL) Solution For Injection (I.V.)4 mL Amber Glass Ampoule with White Ring Snap-Off in Plastic Tray x 5's (Box of 5's) | Rx | Farbe FirmaIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-13144 | Dec 7, 2027 | |
Quinor 4Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Ellebasy Medicale Group Inc.Importer: Despina Pharma Inc. | DRP-14777-03 | Jan 3, 2029 | |
Quinor 8Norepinephrine (as bitartrate) | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)4 mL-net content in 5 mL-capacity Type l amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Ellebasy Medicale Group Inc.Importer: Despina Pharma Inc. | DRP-14776-03 | Jan 3, 2029 | |
QuprinNorepinephrine (as bitartrate) | 1 mg/mL (20 mg/20 mL) Solution for Injection (IV)USP Type I Amber glass ampoule in PVC/PVDC Tray x 5's (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Korea | JLT Pharma Inc. | DRP-17214 | Oct 20, 2030 | |
QuprinNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4mL and 10mg/10mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc. | DRP-8929 | Jun 29, 2031 | |
Rephnor 8Norepinephrine | 2 mg/mL (8 mg/4 mL) Solution for Injection (I.V. Infusion)USP Type I amber glass ampoule x 4 mL (Box of 5's) | Rx | Captab Biotec Unit IIIndia | Finstad Inc.Trader: Morcel Biotech Pvt. Ltd. | DRP-17306 | Nov 14, 2030 | |
RetanephrineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/ 4 mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-19 | Jan 31, 2027 | |
RevaivNorepinephrine (as bitartrate) | 1 mg/ mL Concentrate for Solution for IV InfusionUSP Type I glass ampoule x 2 mL (Box of 1 blister pack x 5's) | Rx | Harson LaboratoriesIndia | BIOCARE LIFESCIENCES, INC. | DRP-7362 | Oct 9, 2027 | |
RevinorNorepinephrine | 1 mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 4mL, 8mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | One Essential Pharma Corp.Importer: Pors Pharma Trading | DRP-16027-04 | Apr 29, 2029 | |
SandineNorepinephrine (as bitartrate) | 1 mg/mL (2 mg/2 mL) and (4 mg/4 mL) Solution for Injection (I.V.)Amber colored USP Type I glass ampoule (2 mL & 4 mL) (Box of 10's) | Rx | Adore Pharmaceuticals Pvt. Ltd.India | Philcare Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-2297 | Oct 9, 2029 | |
Sanor-8Norepinephrine (as bitartrate) | 2 mg / mL (8 mg/ 4 mL) Solution for Injection (I.V. Infusion)4 mL -net content in 5 mL -capacity Type I amber glass ampoule (5 ampoules in clear PVC blister tray per box) | Rx | Ultra Laboratories Private LimitedIndia | Bansan Pharma DistributorImporter: Despina Pharma Inc. | DRP-14776-08 | Jan 3, 2029 | |
SephrineNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for IV injectionUSP Type I Glass Ampoule x 4 mL (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Starpharm, Inc.Importer: H & B Pharma International Inc.Trader: Dalim Biotech Co., Ltd. | DRP-15794-01 | Sep 18, 2029 | |
VALNOREXNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for IV InfusionAmber glass ampoule x 4 ml and 10 ml with white snap off ring (Box of 5’s in a plastic tray) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | SwissPharmatech Co.Importer: AMB HK Enterprises Inc. | DRP-17202-03 | Oct 20, 2030 | |
VaxiprinNorepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Solution for Injection (IV)Type I Amber glass ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | 2 MG IncorporatedImporter: Afree Pharmaceutical Distribution Corp. | DRP-10929-18 | Jan 31, 2027 | |
VenosteqNorepinephrine (as bitartrate) | 1mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Trading OPCImporter: JLT Pharma Inc. | DRP-8929-14 | Jul 6, 2031 | |
VeropresNorepinephrine | 1 mg/mL (4 mg/4 mL and 10 mg/10 mL) Solution for Injection (I.V.)Amber Glass Ampoule with PVC/PVDC Tray x 4 mL and 10 mL (Box of 10's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | The Cathay Drug Co., Inc.Importer: JLT Pharma lnc. | DRP-8929-13 | Jun 17, 2031 | |
ViracentNorepinephrine | 1mg/mL Concentrated Solution for I.V. InjectionType I Amber Glass Ampoule in a Plastic Tray x 1 mL, 2 mL, 4 mL, 6 mL, 8 mL and 10 mL (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Vintel Med EnterprisesImporter: Pors Pharma Trading | DRP-16027-10 | Apr 29, 2029 | |
ViraphrineNorepinephrine (as bitartrate) | 1 mg/mL (4mg/4 mL) Solution for Injection (IV)4 mL Amber Glass Ampoule With Ring Snap-Off in Plastic Tray x 5's (Box of 5’s) | Rx | Farbe Firma Pvt. LtdIndia | Vintel Med EnterprisesImporter: Amb Hk Enterprises Inc. | DRP-13144-03 | Dec 7, 2027 | |
ViraphrineNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for IV InfusionAmber glass ampoule x 4 mL and 10 mL with white snap off ring (Box of 5’s in a plastic tray) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: AMB HK Enterprises, Inc. | DRP-17202-01 | Oct 20, 2030 | |
ZolpicorNorepinephrine (as bitartrate) | 1 mg/mL Concentrate Solution for I.V. InfusionUSP Type I Amber glass ampoule x 2 mL (Box of 1's, 5's and 10's) and x 4 mL (Box of 1's, 5's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Ambitech Pharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11623-01 | Apr 6, 2027 | |
(no brand name)Norepinephrine (as bitartrate) | 1 mg/mL (4 mg/4 mL) Concentrate Solution for IV Infusion4 mL in 5 mL-capacity Type I borosilicate amber glass ampoule (Box of 5 ampoules in PVC tray) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY47980 | Apr 28, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 4 mg/4 mL (1 mg/mL norepinephrine base) sterile, colorless solution in a single-dose amber glass vial. Injection: 4 mg/4 mL (1 mg/mL) norepinephrine base in single-dose glass vial. (3)
Warnings/Precautions
- • Tissue Ischemia: Avoid extravasation of LEVOPHED into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Infuse LEVOPHED into a large vein. To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of an adrenergic blocking agent. (5.1)
- • Hypotension After Abrupt Discontinuation: Sudden cessation of the infusion rate may result in marked hypotension. Reduce the LEVOPHED infusion rate gradually. (5.2)
- • Cardiac Arrhythmias: LEVOPHED may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. (5.3)
- • Allergic Reactions with Sulfite: LEVOPHED contains sodium metabisulfite. Sulfite may cause allergic-type-reactions. (5.4)
5.1 Tissue Ischemia Administration
5.1 Tissue Ischemia Administration of LEVOPHED to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite "normal" blood pressure. Address hypovolemia prior to initiating LEVOPHED [see Dosage and Administration (2.1)].
Avoid LEVOPHED in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction. Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients.
Extravasation of LEVOPHED may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation [see Dosage and Administration (2.1)]. Emergency Treatment of Extravasation To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults.
Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.
5.2 Hypotension
5.2 Hypotension after Abrupt Discontinuation Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the LEVOPHED infusion rate while expanding blood volume with intravenous fluids.
5.3 Cardiac Arrhythmias
5.3 Cardiac Arrhythmias LEVOPHED elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias.
5.4 Allergic Reactions Associated with Sulfite
5.4 Allergic Reactions Associated with Sulfite LEVOPHED contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown.
Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
Drug interactions
- • Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7.1)
- • Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7.4)
7.1 MAO-Inhibiting Drugs Co-administration
7.1 MAO-Inhibiting Drugs Co-administration of LEVOPHED with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of LEVOPHED cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.
7.2 Tricyclic Antidepressants Co-administration
7.2 Tricyclic Antidepressants Co-administration of LEVOPHED with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If administration of LEVOPHED cannot be avoided in these patients, monitor for hypertension.
7.3 Antidiabetics
7.3 Antidiabetics LEVOPHED can decrease insulin sensitivity and raise blood glucose. Monitor glucose and consider dosage adjustment of antidiabetic drugs.
7.4 Halogenated Anesthetics
7.4 Halogenated Anesthetics Concomitant use of LEVOPHED with halogenated anesthetics (e.g., cyclopropane, desflurane, enflurane, isoflurane, and sevoflurane) may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections:
- Tissue Ischemia [see Warnings and Precautions (5.1)]
- Hypotension [see Warnings and Precautions (5.2)]
- Cardiac Arrhythmias [see Warnings and Precautions (5.3)] The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur: Nervous system disorders: Anxiety, headache Respiratory disorders: Respiratory difficulty, pulmonary edema Most common adverse reactions are ischemic injury, bradycardia, anxiety, transient headache, respiratory difficulty, and extravasation necrosis at injection site. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus from hypotension associated with septic shock, myocardial infarction and stroke which are medical emergencies in pregnancy and can be fatal if left untreated.
(see Clinical Considerations). In animal reproduction studies, using high doses of intravenous norepinephrine resulted in lowered maternal placental blood flow. Clinical relevance to changes in the human fetus is unknown since the average maintenance dose is ten times lower (see Data). Increased fetal reabsorptions were observed in pregnant hamsters after receiving daily injections at approximately 2 times the maximum recommended dose on a mg/m 3 basis for four days during organogenesis (see Data).
The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypotension associated with septic shock, myocardial infarction, and stroke are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock, myocardial infarction and stroke may increase the risk of maternal and fetal morbidity and mortality.
Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of norepinephrine on the fetus. Data Animal Data A study in pregnant sheep receiving high doses of intravenous norepinephrine (40 mcg/min, at approximately 10 times the average maintenance dose of 2–4 mcg/min in human, on a mg/kg basis) exhibited a significant decrease in maternal placental blood flow.
Decreases in fetal oxygenation, urine and lung liquid flow were also observed. Norepinephrine administration to pregnant rats on Gestation Day 16 or 17 resulted in cataract production in rat fetuses. In hamsters, an increased number of resorptions (29.1% in study group vs. 3.4% in control group), fetal microscopic liver abnormalities and delayed skeletal ossification were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day from Gestation Day 7–10).
Mechanism of action
12.1 Mechanism of Action Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The primary pharmacodynamic effects of norepinephrine are cardiac stimulation and vasoconstriction. Cardiac output is generally unaffected, although it can be decreased, and total peripheral resistance is also elevated. The elevation in resistance and pressure result in reflex vagal activity, which slows the heart rate and increases stroke volume.
The elevation in vascular tone or resistance reduces blood flow to the major abdominal organs as well as to skeletal muscle. Coronary blood flow is substantially increased secondary to the indirect effects of alpha stimulation. After intravenous administration, a pressor response occurs rapidly and reaches steady state within 5 minutes.
The pharmacologic actions of norepinephrine are terminated primarily by uptake and metabolism in sympathetic nerve endings. The pressor action stops within 1–2 minutes after the infusion is discontinued.
Pharmacokinetics
Elimination The mean half-life of norepinephrine is approximately 2.4 min.
Excretion Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates.
Only small quantities of norepinephrine are excreted unchanged.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Following initiation of intravenous infusion, the steady state plasma concentration is achieved in 5 min. Distribution Plasma protein binding of norepinephrine is approximately 25%. It is mainly bound to plasma albumin and to a smaller extent to prealbumin and alpha 1-acid glycoprotein. The volume of distribution is 8.8 L.
Norepinephrine localizes mainly in sympathetic nervous tissue. It crosses the placenta but not the blood-brain barrier. Elimination The mean half-life of norepinephrine is approximately 2.4 min. The average metabolic clearance is 3.1 L/min. Metabolism Norepinephrine is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and MAO.
The major metabolites are normetanephrine and 3-methoxyl-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive. Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol. Excretion Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates.
Only small quantities of norepinephrine are excreted unchanged.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Norepinephrine 1 mg/mL, 10 mL Ampule | ₱450.00–₱1,200.00Reference ₱515.20 | per ampule | DPRI procurement range |
| Norepinephrine 1 mg/mL, 2 mL Ampule | ₱71.23–₱338.00Reference ₱93.22 | per ampule | DPRI procurement range |
| Norepinephrine 1 mg/mL, 4 mL Ampule | ₱131.22–₱700.00Reference ₱148.04 | per ampule | DPRI procurement range |
| Norepinephrine (as Bitartate) 2 mg/mL, 4 mL Ampule | ₱1,185.00–₱1,650.00Reference ₱1,185.00 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Norepinephrine (as bitartrate) |
| PNF listing | Inj.: 1 mg/mL, 2 mL and 4 mL ampul (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 1 mg/mL, 10 mL ampule (concentrate solution for infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injectionRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. LEVOPHED · Hospira, Inc. [US FDA-approved label, version 5, June 12, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c7dd2b0-cc10-4db6-bf56-6eb154ebeb10
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

